Recombinant SARS-CoV-2 envelope protein traffics to the trans-Golgi network following amphipol-mediated delivery into human cells.
Cell Membrane
/ drug effects
Coronavirus Envelope Proteins
/ genetics
HeLa Cells
Humans
Lipid Bilayers
/ chemistry
Lysosomes
/ metabolism
Polymers
/ chemistry
Propylamines
/ chemistry
Protein Transport
Recombinant Proteins
/ genetics
Surface-Active Agents
/ chemistry
trans-Golgi Network
/ metabolism
E protein
SARS
amphipol
coronavirus
envelope
insertion
ion channel
lysosomes
membrane
trans-Golgi network
Journal
The Journal of biological chemistry
ISSN: 1083-351X
Titre abrégé: J Biol Chem
Pays: United States
ID NLM: 2985121R
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
17
02
2021
revised:
29
06
2021
accepted:
02
07
2021
pubmed:
9
7
2021
medline:
14
9
2021
entrez:
8
7
2021
Statut:
ppublish
Résumé
The severe acute respiratory syndrome coronavirus 2 envelope protein (S2-E) is a conserved membrane protein that is important for coronavirus (CoV) assembly and budding. Here, we describe the recombinant expression and purification of S2-E in amphipol-class amphipathic polymer solutions, which solubilize and stabilize membrane proteins, but do not disrupt membranes. We found that amphipol delivery of S2-E to preformed planar bilayers results in spontaneous membrane integration and formation of viroporin cation channels. Amphipol delivery of the S2-E protein to human cells results in plasma membrane integration, followed by retrograde trafficking to the trans-Golgi network and accumulation in swollen perinuclear lysosomal-associated membrane protein 1-positive vesicles, likely lysosomes. CoV envelope proteins have previously been proposed to manipulate the luminal pH of the trans-Golgi network, which serves as an accumulation station for progeny CoV particles prior to cellular egress via lysosomes. Delivery of S2-E to cells will enable chemical biological approaches for future studies of severe acute respiratory syndrome coronavirus 2 pathogenesis and possibly even development of "Trojan horse" antiviral therapies. Finally, this work also establishes a paradigm for amphipol-mediated delivery of membrane proteins to cells.
Identifiants
pubmed: 34237302
pii: S0021-9258(21)00740-7
doi: 10.1016/j.jbc.2021.100940
pmc: PMC8256659
pii:
doi:
Substances chimiques
Coronavirus Envelope Proteins
0
Lipid Bilayers
0
Polymers
0
Propylamines
0
Recombinant Proteins
0
Surface-Active Agents
0
amphipol A8-35
0
envelope protein, SARS-CoV-2
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
100940Subventions
Organisme : NIDDK NIH HHS
ID : P30 DK058404
Pays : United States
Organisme : NEI NIH HHS
ID : P30 EY008126
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM112077
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK020593
Pays : United States
Organisme : NIA NIH HHS
ID : RF1 AG056147
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA068485
Pays : United States
Organisme : NIA NIH HHS
ID : F31 AG061984
Pays : United States
Organisme : NIDDK NIH HHS
ID : U24 DK059637
Pays : United States
Commentaires et corrections
Type : UpdateOf
Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of interest The authors declare that they have no conflicts of interest with the contents of this article.